Stella Sarraf, Ph.D., CEO

Dr. Sarraf founded Amydis Diagnostics in 2013 after seeing a clinical need for diagnostics that can enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. Most recently, she was a team member of Foresite Capital Management, a growth capital healthcare fund with over $650 Million in assets under management. Some of the successful investments and exits by Foresite with Dr. Sarraf’s involvement included Wavetec Vision (sold to Alcon in 2014), Ambit Biosciences (acquired by Daiichi Sankyo in 2014 for $410M) and Auspex Pharmaceuticals (sold to Teva for $3.5B in 2015). Prior to Foresite, she worked at Prospect Venture Partners for many years, where she performed scientific, regulatory and commercial diligence on more than 400 investment opportunities from companies in therapeutic and diagnostic areas including the neurological and cognitive disorder space.

Dr. Sarraf is also the founder and managing director of Scientific Consulting. Earlier in her career, Dr. Sarraf spent time at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist supporting numerous high quality development products.

Dr. Sarraf holds a Ph.D. in organic chemistry from Columbia University and earned a B.A. in biochemistry and molecular biology from the University of California, Berkeley.


Richard D’Souza, Ph.D., Chief Technology Officer

Dr. Richard D’Souza is an accomplished senior R&D leader in the industry with 30+ years experience developing and building large and specialty pharmaceutical businesses with many innovative new products for global distribution. His R&D career spans several large healthcare companies including Schering Plough, Procter & Gamble, Pfizer/ Warner Lambert and Johnson & Johnson. He also served as Head of R&D for Bausch & Lomb, a leading specialty ophthalmic company, and its integration into Valeant Pharmaceuticals.

He has drug and device development experience, along with OTC consumer healthcare development, that spans multiple therapeutic categories including allergy, analgesics, anti-inflammatory, respiratory, antibiotic, osteoporesis, dermatology, periodontics, ophthalmology, contact lens, lens care and surgical equipment. Notable brand products that are a result of his efforts, and which have achieved significant annual sales levels in the marketplace include Aleve, Femstat, Listerine, Lotemax, Nicorette, Prolensa, Rogaine, Tylenol line extensions, Zantac and Zyrtec, to name a few.

Dr. D'Souza is a Pharmacist by training and has a Ph.D. in Pharmaceutics from the University of Houston. He has completed business management programs from Harvard Business School, Kellogg Business School and the University of Oxford, England.



Dr. Scott Reines is a research physician with broad drug development experience within various therapeutic areas. Prior to Amydis, he has served in leading roles at MedAvante, Johnson & Johnson and Merck, and currently serves on two Scientific Advisory Boards and Data Safety Monitoring Boards.  As Senior Vice President for CNS, Pain and Translational Medicine at J&J, Dr. Reines oversaw the development and approval of numerous drugs for the treatment of schizophrenia, Alzheimer’s, pain and migraine headache.  Prior to that, Dr. Reines served as Vice President, Clinical Research at Merck with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology.  While there, he oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease and led the development of leading brand drugs for nausea and vomiting, migraine, Parkinson’s and glaucoma.

Dr. Reines served for two years as co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and spent five years on the National Drug Abuse Advisory Council. He holds a bachelor’s degree in chemistry from Cornell University, a Ph.D. in chemistry/molecular biology from Columbia University, and a medical degree from Albert Einstein College of Medicine. He is Board Certified in Psychiatry and Neurology.


DAVID H. CREAN, PH.D., MBA, Chief Business Officer

As Chief Business Officer for Amydis Diagnostics, Inc.. Dr. Crean’s focus is on cultivating relationships with key institutional and individual investors and strategic partners to meet short and long-term growth projections. Concurrent with Amydis, Dr. Crean is also a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 25 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities.

Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). He also serves as a business advisor for several early stage life science companies, is a limited partner with Mesa Verde Venture Partners Fund, an active contributor on the Capital Development Committee for BIOCOM and an active member of San Diego Venture Group (SDVG) and the Association for Corporate Growth (ACG) in San Diego and Orange County.

Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College. Dr. Crean holds FINRA Series 79 and  Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.


Jerry Yang, Ph.D., Chief Scientific Advisor & Founder

A bioorganic chemist with more than a decade of experience in amyloid research, Dr. Yang is currently an Associate Professor of chemistry and biochemistry at the University of California, San Diego, where much of his lab work focuses on the development of small molecules that can aid in the diagnosis, prevention, and intervention of a wide range of human diseases. Dr. Yang is the co-author of more than 60 peer-reviewed papers and is an inventor of more than 20 pending and issued patents. He is the recipient of numerous awards and honors from both private and government agencies, including the American Cancer Society, the Alzheimer’s Association, and the National Science Foundation.

Dr. Yang holds a Ph.D. in chemistry from Columbia University, and received post-doctoral training in chemistry and chemical biology at Harvard University. Dr. Yang has also previously held an appointment as a Visiting Associate Professor of Neurology at Harvard Medical School.


Dan Albosta, Chief Financial Officer

Mr. Albosta is a CPA and finance professional with over 25 years of experience. He has worked in Big 4 public accounting as well as Fortune 500 and startup environments. Most recently, he was Director of Finance at QUALCOMM, Inc. for 8 years. He has developed financial infrastructure to support growing global organizations and provided decision support analysis and technical accounting guidance on organizational and deal structures.

Mr. Albosta holds a Masters of Business Administration Degree with a finance concentration from the University of Pittsburgh and a Bachelor of Science Degree in Accounting from Regis University.